.png){kind=small}
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven
March, 2022.
UroGen Pharma LTD., on signing a $ 100 million term loan financing facility with funds managed by Pharmakon Advisors, L.P.
UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.
UroGen Pharma LTD. Was represented by Partner Yaron Sobol, Senior associate Ben Frenkel and Associate Amit Horovitz from our Corporate and M&A Department.
Click on the first comment to read the full article on Yahoo >>
